Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Target lesion

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44336   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    987 result(s) found for: Target lesion. Displaying page 1 of 50.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2005-002992-34 Sponsor Protocol Number: CRAD001ADE07 Start Date*: 2006-07-20
    Sponsor Name:Deutsches Herzzentrum Berlin
    Full Title: Monocenter, double blinded, prospective, randomized, placebo controlled study investigating prevention of Major Adverse Cardiac Events (MACE) after 6 months by systemic treatment with Everolimus af...
    Medical condition: coronary artery disease coronary intervention with bare metal stents
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2018-003615-22 Sponsor Protocol Number: EXP-1373 Start Date*: 2019-05-28
    Sponsor Name:LEO Pharma A/S
    Full Title: Efficacy and safety of twice-daily application of delgocitinib cream 20 mg/g for 6 weeks in subjects with active discoid lupus erythematosus. A phase 2a exploratory, randomised, double-blind, vehi...
    Medical condition: Discoid lupus erythematosus
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004858 10013072 Discoid lupus erythematosus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) DK (Prematurely Ended) FR (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2005-000713-35 Sponsor Protocol Number: AVI-4126-17 Start Date*: 2005-08-08
    Sponsor Name:AVI BioPharma Inc.
    Full Title: A Phase IIA Study to Evaluate the Safety and Preliminary Efficacy of Resten-MP when used in Conjunction with a Bare Metal Stent in de novo Native Coronary Artery Lesions
    Medical condition: Coronary Artery Stenosis
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2010-022244-20 Sponsor Protocol Number: H 569 000 – 1004 Start Date*: 2010-10-15
    Sponsor Name:Almirall S.A.
    Full Title: Double-blind, randomized, vehicle- and comparator-controlled, multicenter trial to evaluate the efficacy and safety of LAS41007 in the treatment of actinic keratosis
    Medical condition: Patients aged 18 and older suffering from actinic keratosis. Patients to be considered have at least 6 but no more than 16 clinically confirmed AK target lesions of mild to moderate intensity in up...
    Disease: Version SOC Term Classification Code Term Level
    14.0 10040785 - Skin and subcutaneous tissue disorders 10000614 Actinic keratosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2013-002467-26 Sponsor Protocol Number: 480-SFA2013-001 Start Date*: 2013-08-30
    Sponsor Name:480 Biomedical, Inc.
    Full Title: The SPRINT trial: An Evaluation of the 480 Biomedical STANZA™ Drug-Eluting Resorbable Scaffold (DRS) System v1.2 in the Treatment of de novo SFA Lesions
    Medical condition: An evaluation of the safety and performance of the STANZA DRS v1.2 system for the treatment of patients with obstructive superficial femoral artery disease.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2007-000200-32 Sponsor Protocol Number: Version 3.0 19 December 2006 Start Date*: 2007-05-09
    Sponsor Name:KANEKA coorporation
    Full Title: First in Man Feasibility Study with the MAHOROBA Stent
    Medical condition: The study will be performed in patients with symptomatic coronary artery disease (chronic stable angina, silent ischemia, and acute coronary syndrome, excluding ST-elevation myocardial infarction) ...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2020-000875-20 Sponsor Protocol Number: C3291028 Start Date*: 2020-05-14
    Sponsor Name:Pfizer Inc.
    Full Title: A Phase 2b, Multi Center, Randomized, Double-Blind, Vehicle-Controlled, Intra-Participant Study, to Evaluate Efficacy and Safety of Two Regimens of Crisaborole Ointment 2% in Japanese Pediatric and...
    Medical condition: Atopic Dermatitis
    Disease:
    Population Age: Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2010-023779-24 Sponsor Protocol Number: M10-1028 Start Date*: 2010-12-06
    Sponsor Name:Stichting Toegepast Caridologisch Onderzoek
    Full Title: A Comparison of Drug Eluting and Bare Metal Stents with Bivalirudin during PCI or Bivalirudin for 4 hours in Acute Coronary Syndromes. The Eindhoven Reperfusion Study
    Medical condition: Patients with ACS who are scheduled for primary PCI (STEMI) or for immediate PCI < 2.5 hours or early PCI < 48 hours (NSTEMI) and who are pre-treated with HLD clopidogrel
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2015-002071-13 Sponsor Protocol Number: CIP0169 Start Date*: 2016-10-24
    Sponsor Name:Mercator MedSystems, Inc.
    Full Title: Lower-Limb Adventitial Infusion of DexaMethasone via Bullfrog to Reduce Occurence of Restenosis after Percutaneous Transluminal Angioplasty Revascularization
    Medical condition: Patients with clinical evidence of severe claudication or chronic critical limb ischemia with an angiographically significant lesion in the infrapopliteal crural vessels.
    Disease: Version SOC Term Classification Code Term Level
    20.0 10047065 - Vascular disorders 10057525 Peripheral artery occlusion PT
    20.0 10047065 - Vascular disorders 10072563 Peripheral artery stenosis PT
    20.1 10042613 - Surgical and medical procedures 10057518 Peripheral artery angioplasty PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2010-022153-42 Sponsor Protocol Number: ADVANCE Start Date*: 2011-01-10
    Sponsor Name:Cytori Therapeutics, Inc
    Full Title: A phase II trial of safety and efficacy of ADRCs delivered via the intracoronary route in the treatment of patients with ST-elevation acute myocardial infarction – The ADVANCE Trial
    Medical condition: patients with ST-elevation myocardial infarction after PCI with stent
    Disease: Version SOC Term Classification Code Term Level
    14.1 10007541 - Cardiac disorders 10028597 Myocardial infarction acute LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Prematurely Ended) DE (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2005-001680-57 Sponsor Protocol Number: HDP 603 Start Date*: 2005-09-22
    Sponsor Name:Heidelberg Pharma GmbH
    Full Title: Phase II study of fosfluridine tidoxil in an oral multiple dose schedule given once-a-day for 7 consecutive days every 2 weeks in patients with advanced breast and colorectal cancer
    Medical condition: Patiens with confirmed metastatic breast or colorectal cancer. Breast:Pats should have received/failed at least 1 but no more than 2 lines of chemotherapy with taxanes and/or anthracyclines for me...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2012-003666-41 Sponsor Protocol Number: IJBMNLUMEN Start Date*: 2013-05-27
    Sponsor Name:Jules Bordet Institute
    Full Title: The LuMEn study 177Lu-octreotate treatment outcome prediction using Multimodality imaging in refractory neuroEndocrine tumours
    Medical condition: Patients with proved progressive (or refractory to standard systemic therapy available in Belgium at the time of inclusion) neuroendocrine tumors, not amenable to surgical resection with curative i...
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10062476 Neuroendocrine tumor LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2004-005218-35 Sponsor Protocol Number: NSGO-CC-0301 Start Date*: 2006-05-18
    Sponsor Name:Nordic Society of Gynecological Oncology (NSGO)
    Full Title: A phase II study of management of the patients with locally advanced (FIGO III & IVa or stage II unfavorably located lesion) or relapsed vulvar carcinoma
    Medical condition: Locally advanced (FIGO III & IVa or stage II unfavorably located lesion) or relapsed vulvar carcinoma.
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: SE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2020-003742-36 Sponsor Protocol Number: MK-3475-02D Start Date*: 2021-02-16
    Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck &Co.,Inc
    Full Title: A Phase 1/2 Open-Label Rolling-Arm Umbrella Platform Design of Investigational Agents With or Without Pembrolizumab or Pembrolizumab Alone in Participants With Melanoma (KEYMAKER-U02): Substudy 02D
    Medical condition: Melanoma
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10053571 Melanoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned) IT (Trial now transitioned) ES (Ongoing) GR (Trial now transitioned) HU (Trial now transitioned) PL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2010-023482-21 Sponsor Protocol Number: 01/10/CPT/TP3 Start Date*: 2011-04-11
    Sponsor Name:PLIVA HRVATSKA d.o.o.
    Full Title: A Multicentre, Randomised, Double-Blind, Parallel-Group Study of the Efficacy and Safety of a PLIVA Ointment (Calcipotriol + Betamethasone 50 µg/g + 0.5 mg/g ointment) versus Vehicle and Dovobet® i...
    Medical condition: mild to severe plaque psoriasis
    Disease: Version SOC Term Classification Code Term Level
    14.1 10040785 - Skin and subcutaneous tissue disorders 10050576 Psoriasis vulgaris LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: CZ (Completed) SK (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2015-005100-28 Sponsor Protocol Number: PDRN-01-16 Start Date*: 2016-07-18
    Sponsor Name:MASTELLI SRL
    Full Title: A phase IV, single-arm, open-label clinical trial to evaluate the efficacy and safety of PLACENTEX ¿ Polydeoxyribonucleotide i.m. in patients with fibrotic and atrophic cutaneous lesions in sclero...
    Medical condition: Fibrotic and atrophic cutaneous lesions in localized scleroderma diseases.
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004870 10039711 Scleroderma and associated disorders HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2013-002605-65 Sponsor Protocol Number: DOTA2013/DOTATER Start Date*: 2013-11-26
    Sponsor Name:Azienda Ospedaliera di Reggio Emilia Arcispedale S.Maria Nuova/IRCCS
    Full Title: Radioreceptor therapy with labeled somatostatin analogues in tumors with high expression of somatostatin receptors.
    Medical condition: Patients with tumors expressing somatostatin receptors.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-000561-16 Sponsor Protocol Number: CBYL719F12201 Start Date*: 2021-07-01
    Sponsor Name:Novartis Pharma AG
    Full Title: EPIK-P2 - A Phase II double-blind study with an upfront, 16-week randomized, placebo-controlled period, to assess the efficacy, safety and pharmacokinetics of alpelisib (BYL719) in pediatric and ad...
    Medical condition: PIK3CA-related overgrowth spectrum (PROS)
    Disease: Version SOC Term Classification Code Term Level
    21.1 10010331 - Congenital, familial and genetic disorders 10081236 PIK3CA related overgrowth spectrum PT
    Population Age: Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Trial now transitioned) NO (Trial now transitioned) NL (Trial now transitioned) FR (Trial now transitioned) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2020-003929-27 Sponsor Protocol Number: LP0053-2187 Start Date*: 2022-02-08
    Sponsor Name:LEO Pharma A/S (also referred to as LEO Pharma)
    Full Title: Assessing target lesion score via daily photograph capture in subjects with psoriasis vulgaris on the body treated once daily with topical LEO 90100 (calcipotriol 50 mcg/g plus betamethasone 0.5 mg...
    Medical condition: Psoriasis vulgaris
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004858 10050576 Psoriasis vulgaris LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Ongoing) DK (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2011-004538-32 Sponsor Protocol Number: LIMTOP-I Start Date*: 2012-04-04
    Sponsor Name:Moberg Derma
    Full Title: A double-blind, randomized, multi-centre, vehicle-controlled study of efficacy and safety of a new topical formulation with imiquimod (Limtop) applied 1,3 or 7 times weekly during 2 x 2 weeks treat...
    Medical condition: 5-20 clinically confirmed, palpable or visible (grade I or II according to modified Olsen score), nonhyperkeratotic, nonhypertrophic, AK lesions located within a contiguous (25 - 100 cm²) area on t...
    Disease: Version SOC Term Classification Code Term Level
    14.1 10040785 - Skin and subcutaneous tissue disorders 10000614 Actinic keratosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri May 16 15:28:18 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA